ArticleDermatology and therapy2026
Modified Delphi Consensus Recommendations for the Management of Psoriasis in Asia-Pacific.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPsoriasis imposes a substantial clinical and quality-of-life burden across the Asia-Pacific (APAC) region. Despite advances in systemic therapies, variability in disease severity classification, assessment tools, and treatment escalation criteria continues to contribute to undertreatment and delayed access to effective care.
methodsA modified Delphi panel was conducted to develop APAC-contextualised consensus recommendations for psoriasis management. Statements were generated from a literature review and refined through Steering Committee interviews and review. The steering committee (n = 6) and Delphi panellists (n = 12) was comprised of dermatology experts from six APAC markets (Australia, China, Japan, South Korea, Malaysia, Taiwan). Consensus was generated through two structured online voting rounds involving all panellists, followed by a moderated consensus meeting, involving only the steering committee, to deliberate on any remaining non-consensus items. Consensus was defined a priori as ≥ 75% agreement among panellists.
resultsIn rounds 1 and 2, 92/130 (71%) and 17/24 (71%) statements achieved consensus, respectively. Eight statements were discussed during the steering committee meeting, during which consensus was reached on all eight. In total, 121 statements achieved formal consensus, which includes an additional 4 non-consensus statements from round 1 that were retained in the final recommendations based on steering committee determination of clinical relevance. Recommendations focused on severity classification and assessment thresholds, treatment goals and response criteria, and systemic therapy eligibility and escalation.
conclusionThese Delphi-derived recommendations provide a practical, patient-centred framework to standardise psoriasis assessment and guide timely treatment escalation in APAC. Adoption may reduce variability in care, support equitable access to appropriate systemic therapies, and improve outcomes across diverse APAC health systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.